Efficacy of Off-Label Use of Anticancer Drugs in Oncology

   The off-label use of anticancer drugs is widespread in modern oncology. The potential advantages of such prescriptions are associated with exceeding the expected clinical benefi ts over the risks of complications. The off-label use of anticancer drugs demonstrates the inconsistent efficacy of this approach depending on the type of malignancy, the reasons for prescribing these agents and their belonging to a particular pharmacological group. In a number of situations, the clinical benefits of off-label drugs are more convincing than in case of authorized indications. Currently, prescribing the “old” registered anticancer drugs, used in everyday clinical practice, is seen routine. However, labeling does not reflect the full range of indications with strong evidence of safety and efficacy. The paradigm shift toward molecularly targeted therapy and immunotherapy in various malignancies may increase the off-label use of the specified agents. Lack of treatment options for rare forms of malignancies and exhaustion of the possibilities for registered therapy are the major reasons for off-label prescribing targeted drugs based on the identifi ed molecular genetic disorders. In such cases, the concept of precision therapy is oft en implemented by using agents, the clinical efficacy of which is confi rmed by data with a low level of evidence or with no evidence. Studying the eff ectiveness of the off-label use of anticancer agents is necessary to systematize information and develop algorithms for making decisions about the prescription of these drugs in routine clinical practice.

1. Saiyed M. M., Ong P. S., Chew L. Off-label drug use in oncology: a systematic review of literature. J Clin Pharm Th er. 2017; 42 (3): 251–8. DOI: 10.1111/jcpt.12507

2. Joerger M., Schaer-Thuer C., Koeberle D., Matter-Walstra K., Gibbons-Marsico J., Diem S., et al. Off-label use of anticancer drugs in eastern Switzerland: a population-based prospective cohort study. Eur J Clin Pharmacol. 2014; 70 (6): 719–25. DOI: 10.1007/s00228-014-1662-5

3. Herbrand A. K., Schmitt A. M., Briel M., Ewald H., Goldkuhle M., Diem S., et al. Association of supporting trial evidence and reimbursement for off-label use of cancer drugs. JAMA Netw Open. 2021; 4 (3): e210380. DOI: 10.1001/jamanetworkopen.2021.0380

4. Kurzrock R., Gurski L. A., Carlson R. W., Ettinger D. S., Horwitz S. M., Kumar S. K., et al. Level of evidence used in recommendations by the National Comprehensive Cancer Network (NCCN) guidelines beyond Food and Drug Administration approvals. Ann Oncol. 2019; 30 (10): 1647–52. DOI: 10.1093/annonc/mdz232

5. Wei G., Wu M., Zhu H., Han S., Chen J., Zhai C., et al. Label use of antineoplastic drugs to treat malignancies: evidence from China based on a nationwide medical insurance data analysis. Front Pharmacol. 2021; 12: 616453. DOI: 10.3389/fphar.2021.616453

6. Mellor J. D., Van Koeverden P., Yip S. W., Thakerar A., Kirsa S. W., Michael M. Access to anticancer drugs: many evidence-based treatments are off-label and unfunded by the Pharmaceutical Benefits Scheme. Intern Med J. 2012; 42 (11): 1224–9. DOI: 10.1111/j.1445-5994.2012.02751.x.

7. Kalis J. A., Pence S. J., Mancini R. S., Zuckerman D. S., Ineck J. R. Prevalence of off-label use of oral oncolytics at a community cancer center. J Oncol Pract. 2015; 11 (2): e139–43. DOI: 10.1200/JOP.2014.001354

8. Bun S., Yonemori K., Sunadoi H., Nishigaki R., Noguchi E., Okusaka T., et al. Safety and evidence of off-label use of approved drugs at the national cancer center hospital in Japan. JCO Oncol Pract. 2021; 17 (3): e416–25. DOI: 10.1200/OP.20.00131

9. de Vries E. G. E., Cherny N. I., Voest E. E. When is off-label off-road? Ann Oncol. 2019; 30 (10): 1536–8. DOI: 10.1093/annonc/mdz445

10. Rauh S., Mavroeidis L., Ntellas P., Gazouli I., Gkoura S., Papadaki A., et al. Old drug, new clinical use, no man’s land for the indication: an awareness call from European experts. ESMO Open. 2020; 5 (1): e000615. DOI: 10.1136/esmoopen-2019-000615

11. Conroy T., Castan F., Lopez A., Turpin A., Ben Abdelghani M., Wei A. C., et al. Five-year outcomes of FOLFIRINOX vs gemcitabine as adjuvant therapy for pancreatic cancer: a randomized clinical trial. JAMA Oncol. 2022; 8 (11): 1571–8. DOI: 10.1001/jamaoncol.2022.3829

12. Conroy T., Desseigne F., Ychou M., Bouché O., Guimbaud R., Bécouarn Y., et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011; 364 (19): 1817–25. DOI: 10.1056/NEJMoa1011923

13. Cunningham D., Starling N., Rao S., Iveson T., Nicolson M., Coxon F., et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med. 2008; 358 (1): 36–46. DOI: 10.1056/NEJMoa073149

14. Conroy T., Hammel P., Hebbar M., Ben Abdelghani M., Wei A. C., Raoul J. L., et al. FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer. N Engl J Med. 2018; 379 (25): 2395–406. DOI: 10.1056/NEJMoa1809775

15. Moore M. J., Goldstein D., Hamm J., Figer A., Hecht J. R., Gallinger S., et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2007; 25 (15): 1960–6. DOI: 10.1200/JCO.2006.07.9525

16. Pancreatic cancer. Clinical guidelines (approved at a meeting of the Scientific and Practical Council of the Ministry of Health of the Russian Federation (Protocol No. 032-3-4 dated 12. 03. 2021). The Clinical Guidelines Rubricator [Internet]. Moscow; 2021 [cited 2023 May 02]. Available from: https://cr.minzdrav.gov.ru/schema/355_4

17. Pokataev I. A., Gladkov O. A., Zagaynov V. E., Kudashkin N. E., Kuchin D. M., Lyadov V. K. et al. Practice guidelines for medical management of pancreatic cancer. Malignant tumours. 2022; 12 (3s2-1): 530–44 (In Russ.). DOI: 10.18027/2224-5057-2022-12-3s2-530-544

18. Ducreux M., Cuhna A. S., Caramella C., Hollebecque A., Burtin P., Goéré D., et al. Cancer of the pancreas: ESMO Clinical Practice Guide-lines for diagnosis, treatment and follow-up. Ann Oncol. 2015; 26 Suppl 5:v56–68. DOI: 10.1093/annonc/mdv295

19. Pancreatic Adenocarcinoma Version 1.2032. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines ® ) [Internet]. Plymouth; 2022. [cited 2023 May 02] Available from: https://www.researchandmarkets.com/reports/5525422/pancreatic-adenocarcinoma-epidemiology

20. Hammel P., Huguet F., van Laethem J. L., Goldstein D., Glimelius B., Artru P., et al. Effect of chemoradiotherapy vs chemotherapy on survival in patients with locally advanced pancreatic cancer controlled after 4 months of gemcitabine with or without erlotinib: The LAP07 randomized clinical trial. JAMA. 2016; 315 (17): 1844–53. DOI: 10.1001/jama.2016.4324

21. Zarkavelis G., Amylidi A. L., Verbaanderd C., Cherny N. I., Metaxas Y., de Vries E. G. E., et al. Off-label despite high-level evidence: a clinical practice review of commonly used off-patent cancer medicines. ESMO Open. 2023; 8 (1): 100604. DOI: 10.1016/j.esmoop.2022.100604

22. Kurzrock R., Gurski L. A., Carlson R. W., Ettinger D. S., Horwitz S. M., Kumar S. K., et al. Level of evidence used in recommendations by the National Comprehensive Cancer Network (NCCN) guidelines beyond Food and Drug Administration approvals. Ann Oncol. 2019; 30 (10): 1647–52. DOI: 10.1093/annonc/mdz232

23. Upadhyay V. A., Johnson B. E., Landman A. B., Hassett M. J. Real-world analysis of off-label use of molecularly targeted therapy in a large academic medical center cohort. JCO Precis Oncol. 2022; 6: e2100232. DOI: 10.1200/PO.21.00232

24. Lim M., Shulman D. S., Roberts H., Li A., Clymer J., Bona K., et al. Off-label prescribing of targeted anticancer therapy at a large pediatric cancer center. Cancer Med. 2020; 9 (18): 6658–66. DOI: 10.1002/cam4.3349

25. Aguilera D., Mazewski C., Fangusaro J., MacDonald T. J., McNall-Knapp R. Y., Hayes L. L., et al. Response to bevacizumab, irinotecan, and temozolomide in children with relapsed medulloblastoma: a multi-institutional experience. Childs Nerv Syst. 2013; 29 (4): 589–96. DOI: 10.1007/s00381-012-2013-4

26. Spini A., Ciccone V., Rosellini P., Ziche M., Lucenteforte E., Salvo F., et al. Safety of anti-angiogenic drugs in pediatric patients with solid tumors: a systematic review and meta-analysis. Cancers (Basel). 2022; 14 (21): 5315. DOI: 10.3390/cancers14215315

27. Gururangan S., Fangusaro J., Poussaint T. Y., McLendon R. E., Onar-Thomas A., Wu S., et al. Efficacy of bevacizumab plus irinotecan in children with recurrent low-grade gliomas — a Pediatric Brain Tumor Consortium study. Neuro Oncol. 2014; 16 (2): 310–7. DOI: 10.1093/neuonc/not154

28. Hwang E. I., Jakacki R. I., Fisher M. J., Kilburn L. B., Horn M., Vezina G., et al. Long-term efficacy and toxicity of bevacizumab-based therapy in children with recurrent low-grade gliomas. Pediatr Blood Cancer. 2013; 60 (5): 776–82. DOI: 10.1002/pbc.24297

29. Kalra M., Heath J. A., Kellie S. J., Dalla Pozza L., Stevens M. M., Swamy S., et al. Confi rmation of bevacizumab activity, and maintenance of efficacy in retreatment after subsequent relapse, in pediatric low-grade glioma. J Pediatr Hematol Oncol. 2015; 37 (6): e341–6. DOI: 10.1097/MPH.0000000000000371

30. Calò P., Pianton N., Basle A., Vasiljevic A., Barritault M., Beuriat P. A., et al. Bevacizumab as single agent in children and teenagers with optic pathway glioma. Cancers (Basel). 2023; 15 (4): 1036. DOI: 10.3390/cancers15041036

31. Bennebroek C. A. M., van Zwol J., Porro G. L., Oostenbrink R., Dittrich A. T. M., Groot A. L. W., et al. Impact of bevacizumab on visual function, tumor size, and toxicity in pediatric progressive optic pathway glioma: A Retrospective Nationwide Multicentre Study. Cancers (Basel). 2022; 14(24):6087. DOI: 10.3390/cancers14246087

32. 32 Green K., Panagopoulou P., D’Arco F., O’Hare P., Bowman R., Walters B., et al. A nationwide evaluation of bevacizumab-based treatments in pediatric low-grade glioma in the UK: Safety, efficacy, visual morbidity, and outcomes. Neuro Oncol. 2023; 25 (4): 774–85. DOI: 10.1093/neuonc/noac223

33. Schmitt A. M., Walter M., Herbrand A. K., Jörger M., Moffa G., Novak U., et al. Characteristics and survival of patients with cancer with intended off-label use-a cohort study. BMJ Open. 2022; 12 (5): e060453. DOI: 10.1136/bmjopen-2021-060453

34. Ladanie A., Schmitt A. M., Speich B., Naudet F., Agarwal A., Pereira T. V., et al. Clinical trial evidence supporting US food and drug administration approval of novel cancer therapies between 2000 and 2016. JAMA Netw Open. 2020; 3 (11): e2024406. DOI: 10.1001/jamanetworkopen.2020.24406

35. Salas-Vega S., Iliopoulos O., Mossialos E. Assessment of overall survival, quality of life, and safety benefits associated with new cancer medicines. JAMA Oncol. 2017; 3: 382–90. DOI: 10.1001/jamaoncol.2016.4166

36. Alabaku O., Laffey T. N., Suh K., Li M. Trends in endpoint use in pivotal trials and effi cacy for US Food and Drug Administrationapproved solid tumor therapies, 1995–2021. J Manag Care Spec Pharm. 2022; 28 (11): 1219–23. DOI: 10.18553/jmcp.2022.28.11.1219

37. He Q., Li Q., Lv F., Kaitin K.I., Shao L. A survey of survival outcomes for targeted cancer drugs approved by the US food and drug administration. Ther Innov Regul Sci. 2021; 55 (4): 676–84. DOI: 10.1007/s43441-021-00264-1

38. Conti R. M., Bernstein A. C., Villaflor V. M., Schilsky R. L., Rosenthal M. B., Bach P. B. Prevalence of off-label use and spending in 2010 among patent-protected chemotherapies in a population-based cohort of medical oncologists. J Clin Oncol. 2013; 31 (9): 1134–9. DOI: 10.1200/JCO.2012.42.7252

39. van Waalwijk van Doorn-Khosrovani S. B., Pisters-van Roy A., van Saase L., van der Graaff M., Gijzen J., Sleijfer S., et al. Personalised reimbursement: a risk-sharing model for biomarker-driven treatment of rare subgroups of cancer patients. Ann Oncol. 2019; 30 (5): 663–5. DOI: 10.1093/annonc/mdz119

40. Hoefflin R., Lazarou A., Hess M. E., Reiser M., Wehrle J., Metzger P., et al. Transitioning the molecular tumor board from proof of concept to clinical routine: a German single-center analysis. Cancers (Basel). 2021; 13 (5): 1151. DOI: 10.3390/cancers13051151